Results for:(21 found)
Feb 28, 2013 12:09PM on Top StocksBy TheStreet Staff

Pfizer has multiple health care businesses and Elan has Tysabri royalties and a would-be acquirer.

Feb 4, 2013 12:37PM on Top StocksBy TheStreet Staff

A report questions whether the FDA will grant New Chemical Entity status for the phosphate binder.

Jan 28, 2013 12:15PM on Top StocksBy TheStreet Staff

The company's fish-oil pill is finally on pharmacy shelves 6 months after approval.

Jan 2, 2013 12:07PM on Top StocksBy TheStreet Staff

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.

Dec 7, 2012 2:23PM on Top StocksBy MSN Money Partner

Stocks pare earlier gains and turn mixed after the consumer sentiment survey disappoints.

Dec 7, 2012 12:27PM on Top StocksBy TheStreet Staff

The biopharma company raises $100 million in debt financing because potential partners aren't interested in the cholesterol-reducing fish-oil pill.

Nov 20, 2012 1:17PM on Top StocksBy TheStreet Staff

Clinical trials, drug launches and FDA approval decisions fill the calendar for these companies at the start of the new year.



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


How to invest when the world is in chaos

As geopolitical tensions threaten to spin out of control, investors are wondering how best to position their portfolios for the global turmoil.



No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.